Key result
Transcatheter valve-in-valve procedures for structural valve deterioration in Mitroflow bioprostheses resulted in 10% in-hospital mortality and a cumulative survival of 90.9% at 1 year.
Why the study?
Does transcatheter valve-in-valve replacement using balloon-expandable bioprostheses provide safe and effective outcomes in patients with structural valve deterioration of Mitroflow bioprostheses?
Population
11 patients with structural valve deterioration of Mitroflow bioprostheses. All but one were in NYHA class…
Design
Case_series
Follow-up
up to 3 years
Authors
Loading...
Requires careful selection to mitigate risks in Mitroflow valve-in-valve; leaves open need for larger comparative studies.
Observational (n=11)
Does transcatheter valve-in-valve replacement using balloon-expandable bioprostheses provide safe and effective outcomes in patients with structural valve deterioration of Mitroflow bioprostheses?
Transcatheter valve-in-valve procedures with balloon-expandable valves provide good mid-term hemodynamic and clinical results for degenerated Mitroflow bioprostheses, though careful assessment is needed to avoid coronary ostial obstruction.
Mosquera et al. (2018) conducted an observational in Structural valve deterioration in Mitroflow bioprostheses (n=11). Transcatheter valve-in-valve procedures using balloon expandable bioprostheses was evaluated on Cumulative survival at 1 year. Transcatheter valve-in-valve procedures for structural valve deterioration in Mitroflow bioprostheses resulted in 10% in-hospital mortality and a cumulative survival of 90.9% at 1 year.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: